SN Bioscience Granted FDA Fast Track Status for Small Cell Lung Cancer Therapy
Overview
SN Bioscience Co. Ltd., under the leadership of CEO Park Young-hwan, made an announcement on May 7th regarding the FDA's decision to grant Fast Track Designation for SNB-101 (API: SN-38), a novel polymer nanoparticle anticancer medication currently undergoing clinical trials for small cell lung cancer (SCLC). This significant development follows previous designations of SNB-101 as an orphan drug for SCLC and pancreatic cancer. With this recent designation, SNB-101 is poised to address the pressing unmet medical needs in the treatment of SCLC and potentially expedite commercialization post phase 2 clinical trials.
Treatment Landscape for SCLC
- The treatment landscape for SCLC remains challenging, with limited options available.
- Currently, the standard first-line therapy involves a combination of cisplatin and etoposide, while second-line treatments are explored in clinical trials as outlined in the NCCN guidelines.
FTA
- The Fast Track designation aims to streamline the drug development process, expediting both development and review for drugs targeting serious conditions with unmet medical needs.
- This designation facilitates enhanced communication with the FDA and allows for a rolling review of the submission package, thereby accelerating the review process.
- Furthermore, it opens doors for potential accelerated approval post phase 2 clinical trials and priority review following phase 3 completion, contingent upon meeting specific qualifications.
SNB-101
- SNB-101 represents a breakthrough as the world's first nanoparticle anticancer drug developed from the highly insoluble SN-38 through polymer nanoparticles.
- Leveraging nano micelle technology, a core platform of SN Bioscience, SNB-101 has demonstrated promising results in preclinical and phase 1 trials, notably reducing adverse events in the digestive system and exhibiting targeted efficacy in lung cancer patients.
- Phase 1 trials have been successfully completed, with IND approval secured for phase 2 trials in Korea, and plans for global trials in the US and Europe slated for the latter half of this year.
- Beyond SCLC and pancreatic cancer, SNB-101's indications are being explored in other solid cancers such as colon, gastric, and biliary tract cancers, with verification planned through phase 2 trials.
Referred to as SNB-101, this groundbreaking anticancer drug is the first of its kind developed from SN-38 nanoparticles. Notably, SN-38 is the active metabolite of Irinotecan, known for its application in drug-antibody conjugates (ADCs) like Enhertu® and Trodelvy®. Offering enhanced tolerability and safety compared to existing products, SNB-101 is anticipated to be efficacious in lung, pancreatic, and gastric cancers, expanding its therapeutic scope beyond previous indications. Successful scale-up production has been achieved, overcoming the major barrier hindering the clinical progression of existing nano-cancer drugs. Clinical trial products are now manufactured in a dedicated facility adhering to EU GMP standards.
